Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro activities of MK-0826 and 16 other antimicrobials against Bacteroides fragilis group strains.

Literature DB >> 11451700

In vitro activities of MK-0826 and 16 other antimicrobials against Bacteroides fragilis group strains.

C Betriu¹, A Sánchez, M L Palau, M Gómez, J J Picazo.

Abstract

The activity of MK-0826, a new carbapenem, against 309 Bacteroides fragilis group strains was investigated and compared with that of 11 other beta-lactam and 5 non-beta-lactam agents. MK-0826 showed excellent activity (MICs ranged from < or =0.06 to 4 microg/ml). The new carbapenem may be useful in the treatment of mixed anaerobic infections involving B. fragilis group strains.

Entities: Chemical Species

Mesh：

Substances：

Year: 2001 PMID： 11451700 PMCID： PMC90657 DOI： 10.1128/AAC.45.8.2372-2374.2001

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

13 in total

1. In-vitro antimicrobial activity of a carbapenem, MK-0826 (L-749,345) and provisional interpretive criteria for disc tests.

Authors: P C Fuchs; A L Barry; S D Brown
Journal: J Antimicrob Chemother Date: 1999-05 Impact factor: 5.790

2. Trends in antimicrobial resistance among clinical isolates of the Bacteroides fragilis group from 1992 to 1997 in Montreal, Canada.

Authors: A C Labbé; A M Bourgault; J Vincelette; P L Turgeon; F Lamothe
Journal: Antimicrob Agents Chemother Date: 1999-10 Impact factor: 5.191

3. In vitro activities of MK-826 (L-749,345) against 363 strains of anaerobic bacteria.

Authors: H M Wexler; D Molitoris; S M Finegold
Journal: Antimicrob Agents Chemother Date: 2000-08 Impact factor: 5.191

4. Comparative In vitro activities of ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections.

Authors: E J Goldstein; D M Citron; C Vreni Merriam; Y Warren; K L Tyrrell
Journal: Antimicrob Agents Chemother Date: 2000-09 Impact factor: 5.191

5. In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum beta-lactamase-and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates.

Authors: J Kohler; K L Dorso; K Young; G G Hammond; H Rosen; H Kropp; L L Silver
Journal: Antimicrob Agents Chemother Date: 1999-05 Impact factor: 5.191

6. Comparative in vitro activities of carbapenem L-749,345 and other antimicrobials against multiresistant gram-negative clinical pathogens.

Authors: G Jacoby; P Han; J Tran
Journal: Antimicrob Agents Chemother Date: 1997-08 Impact factor: 5.191

7. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species.

Authors: K E Aldridge; D Ashcraft; K Cambre; C L Pierson; S G Jenkins; J E Rosenblatt
Journal: Antimicrob Agents Chemother Date: 2001-04 Impact factor: 5.191

8. Susceptibility patterns and resistance to imipenem in the Bacteroides fragilis group species in Japan: a 4-year study.

Authors: K Bandoh; K Ueno; K Watanabe; N Kato
Journal: Clin Infect Dis Date: 1993-06 Impact factor: 9.079

9. A five-year multicenter study of the susceptibility of the Bacteroides fragilis group isolates to cephalosporins, cephamins, penicillins, clindamycin, and metronidazole in the United States.

Authors: K E Aldridge; M Gelfand; L B Reller; L W Ayers; C L Pierson; F Schoenknecht; R C Tilton; J Wilkins; A Henderberg; D D Schiro
Journal: Diagn Microbiol Infect Dis Date: 1994-04 Impact factor: 2.803